Q-omics provides the consensus-scored CICP20 profile across patient tissues and cancer cell-line models. CICP20 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CICP20 is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, CICP20 RNA expression shows 12,703 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, CHOL, and TGCT as cancer lineages where CICP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP20 survival associations across molecular data types. CICP20 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP20 RNA expression–survival associations across cancer types. High CICP20 expression shows unfavorable associations in KIRC, UCEC, UVM, BLCA and CHOL, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CICP20 RNA expression.
This table summarizes CICP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CICP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP20 shows lower tumor expression in THCA and higher tumor expression in CHOL, BRCA, STAD and KICH. The CHOL box plot shows higher CICP20 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .014).
This table shows molecular features associated with CICP20 in patient tissues and cancer cell lines. In patient samples, CICP20 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
